Navigation Links
First Bedside Gene Test Shows Promise
Date:3/29/2012

By Steven Reinberg
HealthDay Reporter

THURSDAY, March 29 (HealthDay News) -- For the first time, a genetic test done at a patient's bedside helped doctors choose the right medicine, Canadian researchers report.

The test, which can be done by nurses and others, was able to identify patients in whom the blood thinner Plavix might be ineffective, putting the patients at risk for heart attacks or strokes.

"One of the shortcomings we have in medicine right now is that there isn't a quick and effective way of identifying these genetic variants," said lead researcher Dr. Derek So, from the University of Ottawa Heart Institute.

"We have created the world's first point-of-care genetic test," he said. "We now have the means of selecting the right drug for the right patient."

The report was published in the March 29 online edition of The Lancet.

To prove the test works, So's team randomly assigned 200 patients to either receive screening for a gene called CYP2C19*2 using the gene test, or to regular care.

All of the patients had undergone a procedure called angioplasty to open a blocked heart artery and had a stent placed there to keep the vessel open.

Standard care after the procedure is to give patients Plavix to prevent clotting. However, many patients have this gene mutation, which makes the drug ineffective and patients more likely to develop a clot that could result in a heart attack or stroke.

Among those with European ancestry, about 30 percent have this mutation, and among Asians it's as high as 50 percent, the researchers noted.

Normally, after starting a patient on Plavix, a platelet function blood test is done to see how the patient reacts to the drug.

In this study, those getting the gene test were given a low dose of Plavix and the others received a regular dose. Both groups were given the drug so the researchers could judge the accuracy of the rapid gene test using the platelet function test as confirmation.

The researchers found the gene test accurately identified all the patients with the gene mutation. Patients who had the mutation were switched to a newer drug called Effient, which is not affected by this mutation.

After one week, 30 percent of those in the standard group were identified by the platelet function test as having a raised risk for clotting, while none of those in the gene test group showed an increased risk for clotting, So said.

"This is the first step required for personalized medicine," So said. "Ours is a proof-of-concept study. Now that we have this tool we can apply this same technology to different groups of patients and alter patient's therapy. We have taken bench to bedside."

One expert, Dr. Kirk Garratt, the clinical director of interventional cardiovascular research at Lenox Hill Hospital in New York City, thinks more proof is needed of the benefits of this particular test, but its real value is its potential.

"Before anybody can get too worked up about the application of this technology in the clinic, we will have to see evidence that acting on the information provided actually yields benefit," Garratt said.

"There is one really dazzling benefit," he added. "These researchers have now shown that you can take a minimally trained allied health person and do accurate genotyping on patients in the clinic -- that is really big news."

The test is given by taking a swab from the patient's cheek, putting it in a machine and getting a result in about an hour. The test can be done by people who have never done genetic testing after just 30 minutes of training, So said.

Larger trials will be needed to see if the test makes a difference in patient outcomes, So noted. Spartan Biosciences, which makes the test used in the study, funded the trial.

In terms of cost, the machine goes for about $10,000 and each test kit is about $300, So said. That's relatively inexpensive if it prevents patients from getting the wrong drug.

One advantage is that the test can be given before patients receive their first dose of Plavix, So pointed out.

In addition, as Plavix (clopidogrel) becomes a generic drug -- as it is in Canada -- its cost goes down, while the newer drugs like Effient (prasugrel) and Brilinta (ticagrelor) are very expensive and are associated with an increased risk of bleeding, he noted.

Commenting on the study, Dr. Amber Beitelshees, an assistant professor of medicine at the University of Maryland School of Medicine in Baltimore and author of an accompanying journal editorial, said that "for the first time, a point-of-care genetic test has been developed which can be used to rapidly screen individuals who carry a particular gene and may benefit from an anti-platelet drug other than Plavix."

Beitelshees added that "this is important because rapid genotyping is necessary in order for genotype-guided therapy to be incorporated into clinical care of patients undergoing coronary interventions outside of clinical trials."

However, another expert thinks much more needs to be shown about the value of this test before it can start to be widely used.

Dr. Gregg Fonarow, director of the Ahmanson-UCLA Cardiomyopathy Center and co-director of the UCLA Preventative Cardiology Program in Los Angeles, said that "there has been great interest in using genetic testing information to guide selection of medications and dosing, yet to date there has been little evidence that this testing can improve clinical outcomes."

However, Fonarow continued, "as neither genetic testing for variant CYP2C19 or platelet-function testing has been demonstrated to improve clinical outcomes and routine use of these tests are not currently recommended, further studies demonstrating any clinical utility, if any, are needed."

More information

For more on angioplasty, visit the U.S. National Heart, Lung, and Blood Institute.

SOURCES: Derek So, M.D., University of Ottawa Heart Institute, Ottawa, Canada; Amber Beitelshees, Pharm.D., assistant professor, medicine, University of Maryland School of Medicine, Baltimore; Kirk Garratt, M.D., clinical director, interventional cardiovascular research, Lenox Hill Hospital, New York City; Gregg Fonarow, M.D., director, Ahmanson-UCLA Cardiomyopathy Center, and co-director, UCLA Preventative Cardiology Program, Los Angeles; March 29, 2012, The Lancet, online


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Medical Training School, Pima Medical Institute Offering First Bachelor's Degree Program
2. Retired Military Brass Support First Ladys Call to Reduce Child Obesity, Improve Nutrition
3. NASBE Supports First Lady Michelle Obama in Fight Against Childhood Obesity
4. PolicyLink CEO Angela Glover Blackwell Released the Following Statement on First Lady Michelle Obamas Childhood Obesity Initiative
5. MSU launches first anti-counterfeiting research program
6. AMA Joins First Lady in Fight Against Childhood Obesity
7. National Wildlife Federation Says Outdoor Time for Kids Can Help First Lady Achieve Her “Let's Move” Goal
8. First blinded study of venous insufficiency prevalence in MS shows promising results
9. Akron Institute of Herzing University Launches Its First Bachelors Degree Programs to Prepare Students for Even Greater Success in Business, Health Care and IT
10. First Gene Variants Linked to Stuttering Discovered
11. FAB-HOMES™ Presents First Passive House Collection
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
First Bedside Gene Test Shows Promise
(Date:5/23/2016)... ... May 23, 2016 , ... Edward D. Buckingham, M.D ... America's Best Physicians. The annual roster is put out by the National Consumer Advisory ... commitment to outstanding care are considered for this award. , The National Consumer Advisory ...
(Date:5/23/2016)... ... May 23, 2016 , ... Researchers can find themselves in a state of ... at this technique may yield big benefits. Scientists might be surprised to learn how ... cell culture laboratory—and lessen the risk of contamination when working with eukaryotic cells. , ...
(Date:5/23/2016)... ... 2016 , ... In light of National Heat Awareness Day ... intervening at the first sign of their pet overheating is the key to ... keep the body’s temperature within a safe range. Considered a veterinary emergency, heatstroke ...
(Date:5/23/2016)... ... May 23, 2016 , ... The Society for Women’s Health ... to move on from that role. , “No one in Washington led the way ... said SWHR Founder Florence Haseltine, MD, PhD. “We offer our deep gratitude to Phyllis ...
(Date:5/23/2016)... ... May 23, 2016 , ... Hadley Institute for the Blind ... are blind or visually impaired, announces the election of Julie S. Tye as ... Hadley’s Board of Trustees retained Morris & Berger, a firm specializing in non-profit ...
Breaking Medicine News(10 mins):
(Date:5/23/2016)... JERUSALEM , May 23, 2016 ... DNA for detection of multiple diseases; ,Technology to be ... Yissum Research Development Company of the ... entered into a research agreement with Aurum Ventures MKI, the ... the development of a new diagnostic approach for early ...
(Date:5/22/2016)... , May 23, 2016 ... develop its anti-fibrotic and anti-inflammatory compound DS102 in ... as in non-alcoholic steatohepatitis (NASH) patients. ... significantly sequestered in lung tissue and has bronchodilatory, ... after oral administration. The Company will publish further ...
(Date:5/20/2016)... 2016 ReportsnReports.com adds "Plaque ... market research report with comprehensive information on the ... with comparative analysis at various stages, therapeutics assessment ... of administration (RoA) and molecule type, along with ... It also reviews key players involved in the ...
Breaking Medicine Technology: